tradingkey.logo

ADMA Biologics Inc

ADMA
查看詳細走勢圖
19.300USD
-0.240-1.23%
交易中 美東報價延遲15分鐘
4.60B總市值
21.75本益比TTM

ADMA Biologics Inc

19.300
-0.240-1.23%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

-1.23%

5天

+2.60%

1月

+0.47%

6月

+9.66%

今年開始到現在

+12.54%

1年

+10.86%

查看詳細走勢圖

TradingKey ADMA Biologics Inc股票評分

單位: USD 更新時間: 2025-12-24

操作建議

ADMA Biologics Inc當前公司基本面數據相對非常健康,增長潛力很大。當前估值合理,在藥品行業排名14/158位。機構持股佔比非常高,近一個月多位分析師給出公司評級為買入。最高目標價27.25。中期看,股價處於上升通道。近一個月,市場表現一般,但公司基本面和技術面得分較高。目前股價在壓力位和支撐位之間,可以做區間波段操作。

ADMA Biologics Inc評分

相關信息

行業排名
14 / 158
全市場排名
41 / 4562
所屬行業
藥品

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

分析師目標

基於 4 分析師
買入
評級
27.250
目標均價
+40.54%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

ADMA Biologics Inc亮點

亮點風險
ADMA Biologics, Inc. is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The Company manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: ASCENIV (immune globulin intravenous, human-slra 10% liquid) for the treatment of primary humoral immunodeficiency (PI); BIVIGAM (immune globulin intravenous, human) for the treatment of PI; and NABI-HB (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. Through its ADMA BioCenters subsidiary, the Company also operates as an FDA-approved source plasma collector in the United States, which provides its blood plasma for the manufacture of its products.
業績高增長
公司營業收入穩步增長,連續3年增長176.77%
業績轉盈
公司業績轉盈,最新年度盈利美元
估值高估
公司最新PE估值22.02,處於3年歷史高位
機構加倉
最新機構持股228.97M股,環比增加0.04%
PRFDX持倉
明星投資者PRFDX持倉,最新持倉1.94M股

ADMA Biologics Inc新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

ADMA Biologics Inc簡介

ADMA Biologics, Inc. is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The Company manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: ASCENIV (immune globulin intravenous, human-slra 10% liquid) for the treatment of primary humoral immunodeficiency (PI); BIVIGAM (immune globulin intravenous, human) for the treatment of PI; and NABI-HB (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. Through its ADMA BioCenters subsidiary, the Company also operates as an FDA-approved source plasma collector in the United States, which provides its blood plasma for the manufacture of its products.
公司代碼ADMA
公司ADMA Biologics Inc
CEOGrossman (Adam S)
網址https://www.admabiologics.com/

常見問題

ADMA Biologics Inc(ADMA)的當前股價是多少?

ADMA Biologics Inc(ADMA)的當前股價是 19.300。

ADMA Biologics Inc 的股票代碼是什麼?

ADMA Biologics Inc的股票代碼是ADMA。

ADMA Biologics Inc股票的52週最高點是多少?

ADMA Biologics Inc股票的52週最高點是25.670。

ADMA Biologics Inc股票的52週最低點是多少?

ADMA Biologics Inc股票的52週最低點是13.500。

ADMA Biologics Inc的市值是多少?

ADMA Biologics Inc的市值是4.60B。

ADMA Biologics Inc的淨利潤是多少?

ADMA Biologics Inc的淨利潤為197.67M。

現在ADMA Biologics Inc(ADMA)的股票是買入、持有還是賣出?

根據分析師評級,ADMA Biologics Inc(ADMA)的總體評級為買入,目標價格為27.250。

ADMA Biologics Inc(ADMA)股票的每股收益(EPS TTM)是多少

ADMA Biologics Inc(ADMA)股票的每股收益(EPS TTM)是0.887。
KeyAI